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mir-29 Regulates Mcl-1 Protein Expression and Apoptosis
Justin L. Mott, Shogo Kobayashi, Steven F. Bronk, and Gregory J. Gores
Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and
Hepatology, Mayo Clinic College of Medicine, Rochester, MN

Abstract
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Cellular expression of Mcl-1, an anti-apoptotic Bcl-2 family member, is tightly regulated. Recently,
Bcl-2 expression was shown to be regulated by microRNAs, small endogenous RNA molecules that
regulate protein expression through sequence-specific interaction with messenger RNA. By analogy,
we reasoned that Mcl-1 expression may also be regulated by microRNAs. We chose human
immortalized, but non-malignant, H69 cholangiocyte and malignant KMCH cholangiocarcinoma
cell lines for these studies because Mcl-1 is dysregulated in cells with the malignant phenotype. In
silico analysis identified a putative target site in the Mcl-1 mRNA for the mir-29 family, and we
found that mir-29b was highly expressed in cholangiocytes. Interestingly, mir-29b was
downregulated in malignant cells, consistent with Mcl-1 protein upregulation. Enforced mir-29b
expression reduced Mcl-1 protein expression in KMCH cells. This effect was direct, as mir-29b
negatively regulated expression of an Mcl-1 3’ untranslated region (UTR)-based reporter construct.
Enforced mir-29b expression reduced Mcl-1 cellular protein levels and sensitized the cancer cells to
TRAIL cytotoxicity. Transfection of non-malignant cells (that express high levels of mir-29) with a
locked-nucleic acid antagonist of mir-29b increased Mcl-1 levels and reduced TRAIL-mediated
apoptosis. Thus mir-29 is an endogenous regulator of Mcl-1 protein expression and, thereby,
apoptosis.
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Mcl-1 is a potent multidomain anti-apoptotic protein of the Bcl-2 family containing Bcl-2homology domains BH1í3 that heterodimerizes with Bcl-2 family members. Specifically,
Mcl-1 binds to the BH3-only proteins Bim, Bid, Bik, Noxa, and Puma (Chen et al., 2005), as
well as Bak (Cuconati et al., 2003). Binding to Bid and Bim protects against TRAIL (tumor
necrosis factor-related apoptosis-inducing ligand)-induced cell death. Either depletion of
Mcl-1 (Nijhawan et al., 2003) or disruption of the interaction between Mcl-1 and Bak coincides
with apoptosis following a cytotoxic stimulus (Leu et al., 2004). Still, the mechanism by which
Bcl-2 family members modulate apoptosis remains incompletely understood (Willis & Adams,
2005).
Tight regulation of Mcl-1 protein levels is necessary; on one hand, insufficient Mcl-1 can result
in inappropriate cell death and on the other hand, over-expression poses a risk of cellular
transformation. For example, conditional deletion of Mcl-1 results in bone marrow failure due
to inappropriate apoptosis of precursor cells (Opferman et al., 2003), whereas transgenic mice
with constitutive Mcl-1 expression develop hematologic malignancies (Zhou et al., 2001).
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Mcl-1 overexpression is commonly observed in cancers (Konopleva et al., 2006), including
cholangiocarcinoma (Kobayashi et al., 2005), and overexpression correlates with cancer
prognosis and recurrence (Kaufmann et al., 1998; Wuilleme-Toumi et al., 2005). In
cholangiocarcinoma, overexpression of Mcl-1 causes resistance to TRAIL-induced apoptosis
while suppression sensitizes cells to apoptosis (Taniai et al., 2004).
The regulation of Mcl-1 protein levels is complex. Transcriptionally, Mcl-1 mRNA is
upregulated by cytokines IL-3, IL-5, IL-6, IL-15, IL-22, and IFN-alpha, as well as by GMCSF, and EGFR activation (reviewed by Michels et al., 2005). At the protein level, the halflife of Mcl-1 is approximately 2í4 hours. Ubiquitination by the E3-ligase Mule leads to rapid
degradation by the proteasome, and prevention of ubiquitination increases Mcl-1 levels and
enhances protection (Zhong et al., 2005). Alternatively, bile acids prevent Mcl-1 turnover
through an EGFR-dependent pathway, again enhancing protection (Yoon et al., 2002). Thus
Mcl-1 is regulated by multiple cellular processes.
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Given the complexities of Mcl-1 regulation, it is highly likely that other mechanisms exist.
Recent work has described a potential new mechanism for protein regulation, namely through
microRNAs (Bartel, 2004). MicroRNAs act as endogenous sequence-specific suppressors of
translation, and thus can decrease target protein expression (Lewis et al., 2005). The
microRNA:target interaction occurs through base pairing of the “seed region” of the microRNA
(nucleotides 2í7) to the cognate target (Lewis et al., 2005). While relatively few microRNA
targets have been experimentally described, significantly the prototypical anti-apoptotic
protein Bcl-2 is a target of microRNA regulation. mir-15 and mir-16 have base
complementarity (including the seed region) to the Bcl-2 mRNA, and overexpression of
mir-15/16 leads to decreased Bcl-2 protein and increased cell death (Cimmino et al., 2005).
Although microRNAs potentially regulate expression of other Bcl-2 family proteins, this
mechanism of Mcl-1 regulation has not been explored. The objective of the current study was
to examine the role of microRNAs in regulation of Mcl-1 expression.

RESULTS
Mcl-1 is a potential target of mir-29 microRNA regulation
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Predicted Mcl-1-binding microRNAs were located by computer search (Supplemental
Material) and include mir-29b, mir-125b, mir-153, mir-193b, and mir320 (Figure 1a). Given
the overexpression of Mcl-1 in malignant cholangiocarcinoma cells, we postulated the Mcl-1inhibitory microRNA would be reduced in these cells, but more abundantly expressed in the
H69 nonmalignant cholangiocyte cells which minimally express Mcl-1. Therefore, Northern
blot analysis was performed for microRNAs in H69 cells. Only mir-29 was abundantly
expressed in the mature form in H69 cholangiocytes (Figure 1b). Note that the precursor form
was detected for all examined microRNAs. Several possible mechanisms could explain this
regulation, including regulation of expression through the maturation or nuclear export process
(Lee et al., 2002), or potentially through degradation of the mature microRNA. There is perfect
complementarity between mir-29b and the 3’UTR of Mcl-1 over the first 9 nucleotides
(including the 2í7 seed), consistent with a bona fide mir-29 binding site (Table 1, Supplemental
Material). The three isoforms of mir-29 (a, b, c) share the first 9 nucleotides with minor
divergence thereafter, suggesting all isoforms potentially target Mcl-1.
mir-29 expression is reduced in cholangiocarcinoma cell line
If mir-29b is a potent regulator of Mcl-1 protein expression, then mir-29 should be
downregulated in cholangiocarcinoma cells which richly express Mcl-1 protein relative to the
H69 cells which have minimal Mcl-1 protein expression (Figure 2a). Consistent with a role for
mir-29b in Mcl-1 regulation, mir-29b is abundantly expressed in H69 cells, and is
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downregulated in the KMCH cholangiocarcinoma cells (Figure 2b). A microRNA microarray
(Genosensor, Tempe AZ), demonstrated that the mir-29b isoform is the most abundant isoform
in H69 and KMCH cells (data not shown). The probe employed for the Northern (mir-29a)
should hybridize to all mir-29 isoforms under the present conditions; however, only a single
band in the range of 18í26 nucleotides was observed (Figure 2b). Likely, the mir-29b product
(23 nucleotides) predominates in this cell type. Further evidence that mir-29b is detectible with
the mir-29a probe is the observation that transfection with pre-mir-29b results in an increased
signal on Northern blot analysis using the mir-29a probe (Figure 3b). Consistent with the
Northern blot analysis, the real-time RT-PCR assay demonstrates downregulation of mir-29b
in KMCH cells (Figure 2c). In a subset (one-third) of cryopreserved human
cholangiocarcinoma specimens (n=6), mir-29b was downregulated approximately 7-fold by
real-time RT-PCR. Thus, mir-29b can be downregulated in human cholangiocarcinoma cells
and tissue.
mir-29b downregulates Mcl-1 protein
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MicroRNAs regulate gene expression through decreased translation, increased degradation of
the target message, or both (Valencia-Sanchez et al., 2006). Despite substantial differences in
protein expression, real-time PCR demonstrated Mcl-1 messenger RNA copy numbers were
similar between H69 and KMCH cells. Specifically, H69 cells expressed 6.98 ± 2.6 copies of
Mcl-1 messenger RNA for every 1000 copies of 18S RNA (internal control) and KMCH cells
expressed 6.28 ± 0.9 copies of Mcl-1 mRNA per 1000 copies of 18S RNA. This disparity
between message and protein expression is consistent with microRNA regulation of translation.
To ascertain if mir-29b regulates Mcl-1, we transfected KMCH cells (which have reduced
endogenous mir-29b levels) with single-stranded precursor mir-29b. Control experiments were
performed in the same manner, except using mock-transfected cells, or cells transfected with
an RNA of the same size, antisense to the precursor transfected in experimental cells. The
transfection efficiency was examined by transfecting cells with a fluorescently-labeled
precursor mir-29b RNA, and was >90% (Figure 3a). Cells were transfected with either 20 or
50 nM mir-29b precursor. Northern blot confirmed that the precursor is processed to mature
mir-29b (Figure 3b). Increased expression of mir-29b following transfection was also observed
by real-time RT-PCR (not shown). Immunofluorescence demonstrated decreased Mcl-1
reactivity in mir-29b transfected cells (Figure 3c). Similarly, KMCH cells transfected with the
mir-29b expression plasmid p29b had reduced Mcl-1 protein by Western blot (Figure 3d). The
reduction in Mcl-1 protein was specific as protein levels of Bax, Bak, Bcl-XL, and Bcl-2 were
not altered.
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To avoid the cellular stress of the transient transfection process, we also generated two KMCH
cell lines stably transfected with mir-29b (K-mir-29í6 and K-mir-29í19). Northern blot
analysis confirmed the overexpression of mir-29b compared to the parental KMCH cells
(Figure 3e). Consistent with our other data, and with a role for mir-29b in regulating Mcl-1,
these mir-29b overexpressing cells also manifest reduced steady-state levels of Mcl-1 protein
(Figure 3f). Thus mir-29b acts as a regulator of Mcl-1 expression.
mir-29b does not affect Mcl-1 mRNA expression
To determine the effect of mir-29b on Mcl-1 mRNA levels, total RNA was isolated from
KMCH cells stably transfected with the mir-29b expression construct p29b and parental cells.
Mcl-1 message was quantitated by real-time RT-PCR. The two stable cell lines K-mir-29í6
and K-mir-29í19 had no decrease in Mcl-1 message, expressing 82% and 83% as much Mcl-1
mRNA as parental KMCH cells (p values not significant).
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To demonstrate that the negative effect of mir-29b on Mcl-1 expression was direct, we used a
luciferase reporter assay. The alignment of mir-29b with the 3’UTR insert is illustrated (Figure
4a). Cotransfection of HeLa cells with the parental luciferase construct (without the Mcl-1
3’UTR) plus the mir-29b expression vector does not significantly change expression of the
reporter (Figure 4b). However, when the mir-29 target site from the Mcl-1 3’UTR is inserted
into the luciferase construct, expression of luciferase is strongly decreased when cotransfected
with mir-29b (Figure 4b). This suppression is relieved by a single base mutation in the binding
site (Figure 4b). These data were replicated in KMCH cells (not shown), again the only effect
was when both mir-29b and its target sequence were present. Thus, mir-29 directly inhibits
expression of Mcl-1 by binding to its target sequence.
mir-29b sensitizes cells to apoptosis
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KMCH cholangiocarcinoma cells are resistant to TRAIL-induced cell death compared to their
non-malignant counterpart H69 cells due to Mcl-1 expression (Taniai et al., 2004). Therefore,
we postulated that transfection of KMCH with mir-29b, which downregulates cellular Mcl-1
levels, would sensitize the cells to TRAIL cytotoxicity. Indeed, transfection with 50 nM
precursor mir-29b RNA sensitized KMCH cells to TRAIL-induced apoptosis (Figure 5).
Enhanced apoptosis, as assessed by morphology (Figure 5a) or caspase 3/7 activity (Figure 5b)
was observed in TRAIL-treated cells following mir-29b transfection. These data suggest that
mir-29b downregulation of Mcl-1 is functional as it sensitizes cells to apoptosis. If this concept
is correct, then inhibition of mir-29b should increase Mcl-1 expression and increase cellular
resistance to apoptosis.
To test this postulate, H69 cells were employed as they abundantly express mir-29 with a
corresponding relative reduction of cellular Mcl-1 protein levels. mir-29b function was
inhibited by transfecting cells with a locked nucleic acid (LNA) oligonucleotide that binds
tightly to mir-29b. Transfection with a mir-29b-targeting LNA increases Mcl-1 cellular protein
levels (Figure 6a). The increased cellular Mcl-1 levels due to antagonism of mir-29b by LNA
protected the H69 cells from TRAIL cytotoxicity (Figure 6b). Because KMCH cells only
weakly express mir-29b, antagonism of mir-29b by LNA transfection in these cells was similar
to control, and did not further alter Mcl-1 overexpression (Figure 6a), nor suppress TRAIL
cytotoxicity (Figure 6b). Consistent with the morphologic assessment of cell death, LNA
transfection protected H69 cells from caspase 3/7 activation upon TRAIL treatment (Figure
6c). KMCH cells were already resistant to TRAIL-induced caspase activation and did not enjoy
further protection upon LNA transfection (Figure 6c). Taken together, the data support a role
for mir-29b-mediated Mcl-1 regulation that modulates cellular sensitivity to TRAIL.
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DISCUSSION
Several observations suggest that mir-29b regulates Mcl-1 expression. For example, enforced
mir-29b expression reduces cellular Mcl-1 protein levels while LNA inhibition of mir-29b
function increases Mcl-1 protein expression. The ability of mir-29b to regulate Mcl-1 protein
expression is likely direct as it binds to the 3’UTR region of Mcl-1 messenger RNA, with
complementarity to the mir-29b seed region. mir-29b appears to inhibit Mcl-1 protein
translation as steady state Mcl-1 mRNA levels are similar between KMCH and H69 cells
despite their disparate expression of mir-29b, and Mcl-1 mRNA levels are not different in
KMCH cells stably overexpressing mir-29b versus parental cells.
Our studies have implications for cancer biology. Increasing evidence suggests that
microRNAs play a role in carcinogenesis by altering transcription of oncogenes and tumor
suppressor genes (McManus, 2003). Our data extend these concepts by suggesting that
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decreased mir-29b expression also helps cells evade cell death, a cardinal feature of cancer
cells. The decreased expression of mir-29b with concomitant enhancement of Mcl-1 expression
may explain in part the up-regulation of Mcl-1 in this cancer. Indeed, a convincing precedent
for microRNA regulation of Bcl-2 proteins has been established (Cimmino et al., 2005). Our
limited data demonstrating a down-regulation of mir-29b in a subset of human
cholangiocarcinomas also supports this concept.
mir-29 may have a broader role in tumor biology in addition to a potential role in
cholangiocarcinoma suggested in the current study. For example, mir-29 is also downregulated in aggressive CLL, colon, and breast cancer (Calin et al., 2005; Cummins et al.,
2006; Yanaihara et al., 2006). mir-29a and mir-29b1 are expressed on the same transcript from
a locus at chromosome 7q32 which coincides with the common fragile site FRA7H, and may
allow for frequent mir-29 down-regulation in these cancers (Calin et al., 2004). Loss of
heterozygosity at this site is associated with more aggressive prostate cancer (Neville et al.,
2002). Iorio et al. found that mir-29 was down-regulated in aggressive breast cancer specimens;
those that lacked estrogen and progestin receptors (mir-29b), and those with vascular invasion
(Iorio et al., 2005). The relationship between loss of mir-29b expression in human cancer and
regulation of target proteins such as Mcl-1 merits further examination.
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In summary, Mcl-1 protein expression can be regulated by mir-29b. These studies extend our
knowledge of Mcl-1 expression, a key anti-apoptotic protein which has been referred to as a
“linchpin in the network of anti-apoptotic regulators” (van Delft & Huang, 2006). Thus, in
addition to transcriptional and post-transcriptional regulation, Mcl-1 is also regulated at the
translational level by microRNA, an emerging paradigm for many proteins (Bartel, 2004).
Based on these concepts, we propose that the regulation of mir-29b may be a key process in
Mcl-1 biology and pathobiology. In particular, mechanisms to enhance mir-29b expression
which would reduce cellular Mcl-1 levels could potentially be of value in cancer therapy.

MATERIALS AND METHODS
The Methods for cell lines and human tissue, mir-29 binding site sequencing, transient
transfection, microRNA array, fluorescent microRNA transfection, Northern blot conditions,
reporter gene assay, and Western blot antibodies are available as Supplemental Materials.
MicroRNA target predictions
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Computer-based programs were used to predict microRNAs that potentially bind Mcl-1. Using
“MCL1” as a search term, we queried Miranda (John et al., 2004)
(http://www.microrna.org/), Pictar (Krek et al., 2005) (http://pictar.bio.nyu.edu/), and
miRBase Targets (Griffiths-Jones et al., 2006) (http://microrna.sanger.ac.uk/). Prediction
algorithms and known microRNAs change over time, and the analysis included here is from
June 2006.
Northern blotting
Total RNA isolation was performed per the manufacturers instructions, and for some
experiments, small RNA species were enriched (mirVana kit, Ambion, Austin TX). For
Northern blotting, the fraction enriched for small RNAs (1 microgram per well) or total RNA
(5 micrograms) was run on a 15% polyacrylamide-urea gel, transferred to a Zeta-probe
membrane (BioRad, Hercules CA), and UV-crosslinked.
Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Real-time RTPCR for human Mcl-1 was performed as described (Yoon et al.) using a capillary
thermocycler (Lightcycler, Roche, Mannheim, Germany). For microRNA RT-PCR the
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dominant family member was determined by the microRNA array (below) and mir-29b, -125b,
-153, -193b, and -320 were detected (Applied Biosystems, Foster City CA). As a control, the
small housekeeping RNA Z30 was amplified and quantitated. RT-PCR was performed on 50
ng total RNA. The mir-29b reaction was tested on 0.01 ng to 100 ng of target RNA (H69 cells)
and the plot of cycle number versus log RNA concentration was linear over this range. The
PCR products for mir-29b, -125b, -153, -193b, and -320 were cloned (pCR2.1 TOPO,
Invitrogen, Carlsbad CA) and sequenced to confirm the product identity. Products for mir-29b
and Z30 were gel purified (single visible band) and quantitated by absorbance at 260 nm to
generate a standard curve (linear at least between 103 and 109 copies).
RNA transfection
In vitro transcribed RNA (MegaScript; Ambion, Austin TX) was generated corresponding to
approximately the precursor stem-loop of mir-29b-1. This was synthesized using a gel-purified
PCR-generated amplicon containing the precursor for mir-29b-1 using genomic DNA as
template (forward primer 5’GGTACCGGTTGTCTTGGGTTTATTG; reverse
5’GAATTCAAATACTTCAGAGCTG). The T7 promoter was added at the 5’ end of the
forward primer by a second PCR. Control RNA (antisense to the pre-mir-29 sequence) was
generated from the same amplicon except that the T7 promoter was separately added to the 5’
end of the reverse primer by PCR.
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Antagonism of mir-29b was through transfection of a chimeric locked nucleic acid (LNA)/
DNA oligonucleotide designed to hybridize to mir-29. The sequence used was 5’ AACACT
*G*A*T*T TCAATGGT *G*C*T*A (Proligo, Boulder CO) where * before a base denotes
an LNA base (2’O-4’C-methylene modified).
Luciferase assay
The p-MIR-Report plasmid (Ambion, Austin TX) was modified by insertion of the Mcl-1derived mir-29b binding site or a single-base mutant thereof into the 3’UTR. These reporters
were transfected into HeLa or KMCH cells, and transfection efficiency corrected by a renilla
luciferase vector (pRL-CMV, Promega, Madison WI). The p29b expression plasmid was cotransfected where indicated. HeLa cells were chosen because they are readily transfected, and
they express low levels of endogenous mir-29 (Lagos-Quintana et al., 2001). Comparable
results were observed in KMCH cells.
Western blotting

NIH-PA Author Manuscript

Proteins were resolved on 12% polyacrylamide gels, transferred to nitrocellulose membrane
(Biorad, Hercules CA), and blocked with 5% nonfat dairy milk in Tris-buffered saline (20 mM
Tris, 150 mM NaCl, pH 7.4) with 0.1% Tween-20.
Immunofluorescence
Phosphate buffered saline (PBS; 0.9% sodium chloride, 20 mM sodium phosphate, pH 7.4)
was used for all wash steps (three times five minutes each). Cells grown on glass coverslips
were washed, and then fixed with paraformaldehyde (3% paraformaldehyde in 100 mM PIPES
pH 6.95, 1 mM EGTA, 3 mM magnesium sulfate). Cells were washed of fixative and
permeabilized with 0.0125% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic
acid (CHAPS; in PBS). Non-specific protein binding was blocked with 5% normal goat serum
(Sigma, St. Louis MO), 5% glycerol in PBS. Mcl-1 was detected using a monoclonal antibody
(1:250 dilution in blocking buffer, Epitomics, Burlingame CA), washed and detected with
Texas-red conjugated secondary antibody (Molecular Probes, Eugene OR). Finally cells were
washed with PBS, then rinsed with water and mounted onto slides using ProLong Antifade Kit
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(Molecular Probes, Eugene OR). Images were captured by confocal microscopy using a Zeiss
LSM 510 inverted microscope (Carl Zeiss Inc., Thornwood, New Jersey).
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Cell death assays
Cells plated at least one day prior were transfected with pre-mir-29b and incubated 22 hours.
TRAIL (R&D Systems, Minneapolis MN) was then added (2 ng/mL final) in fresh media and
the cells were treated for 4 hours. Cells were stained with 4’,6-diamidino-2-phenylindole
dihydrochloride (DAPI, 1000X stock = 5 mg/mL in water; Sigma, St. Louis MO) and observed
under fluorescence microscopy. Apoptosis was quantitated by counting nuclei with
characteristic apoptotic changes. Media was changed for untreated cells at the same time
TRAIL was added to treated cells to keep conditions the same. Caspase 3/7-like activity
(DEVD-ase activity) was measured using the ApoOne Kit (Promega, Madison WI).
Statistical analysis
Data are expressed as mean ± S.E.M., all blots represent at least three separate experiments.
Cell death data shown were done in triplicate for each experiment, and are representative of
three or more experiments. Comparison of the expression of mir-29b using RT-PCR was made
using the Students T-test, for all other analyses multiple comparisons were possible so ANOVA
was used with Bonferroni post hoc correction.

NIH-PA Author Manuscript

ACKNOWLEDGEMENTS
The authors thank Erin Nystuen-Bungum for secretarial assistance. Grant support was from the National Institutes of
Health DK59427 (G.J.G).

REFERENCES

NIH-PA Author Manuscript

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.
[PubMed: 14744438]
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature
associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med
2005;353:1793–801. [PubMed: 16251535]
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes
are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U
S A 2004;101:2999–3004. [PubMed: 14973191]
Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival
Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell
2005;17:393–403. [PubMed: 15694340]
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce
apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944–9. [PubMed: 16166262]
Cuconati A, Mukherjee C, Perez D, White E. DNA damage response and MCL-1 destruction initiate
apoptosis in adenovirus-infected cells. Genes Dev 2003;17:2922–32. [PubMed: 14633975]
Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr. Sjoblom T, et al. The colorectal microRNAome.
Proc Natl Acad Sci U S A 2006;103:3687–92. [PubMed: 16505370]
Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences,
targets and gene nomenclature. Nucleic Acids Res 2006;34:D140–4. [PubMed: 16381832]
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression
deregulation in human breast cancer. Cancer Res 2005;65:7065–70. [PubMed: 16103053]
John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol
2004;2:e363. [PubMed: 15502875]
Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, et al. Elevated expression of the
apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91:991–1000. [PubMed:
9446661]

Oncogene. Author manuscript; available in PMC 2008 June 20.

Mott et al.

Page 8

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1
up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.
Gastroenterology 2005;128:2054–65. [PubMed: 15940637]
Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis
sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell
2006;10:375–88. [PubMed: 17097560]
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target
predictions. Nat Genet 2005;37:495–500. [PubMed: 15806104]
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small
expressed RNAs. Science 2001;294:853–8. [PubMed: 11679670]
Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular
localization. Embo J 2002;21:4663–70. [PubMed: 12198168]
Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes
disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004;6:443–50. [PubMed: 15077116]
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell 2005;120:15–20. [PubMed: 15652477]
McManus MT. MicroRNAs and cancer. Semin Cancer Biol 2003;13:253–8. [PubMed: 14563119]
Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol 2005;37:267–71. [PubMed:
15474972]
Neville PJ, Conti DV, Paris PL, Levin H, Catalona WJ, Suarez BK, et al. Prostate cancer aggressiveness
locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia
2002;4:424–31. [PubMed: 12192601]
Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the
initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003;17:1475–86. [PubMed:
12783855]
Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance
of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003;426:671–6. [PubMed:
14668867]
Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, et al. Mcl-1 mediates tumor
necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Cancer Res 2004;64:3517–24. [PubMed: 15150106]
Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by
miRNAs and siRNAs. Genes Dev 2006;20:515–24. [PubMed: 16510870]
van Delft MF, Huang DC. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res
2006;16:203–13. [PubMed: 16474435]
Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol
2005;17:617–25. [PubMed: 16243507]
Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is
overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia
2005;19:1248–52. [PubMed: 15902294]
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular
profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189–98. [PubMed: 16530703]
Yoon J-H, Werneburg NW, Higuchi H, Canbay AE, Kaufmann SH, Akgul C, et al. Bile Acids Inhibit
Mcl-1 Protein Turnover via an Epidermal Growth Factor Receptor/Raf-1-dependent Mechanism.
Cancer Res 2002;62:6500–6505. [PubMed: 12438243]
Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the
polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005;121:1085–95. [PubMed: 15989957]
Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD, et al. MCL1 transgenic mice exhibit a high
incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001;97:3902–
9. [PubMed: 11389033]

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Oncogene. Author manuscript; available in PMC 2008 June 20.

Mott et al.

Page 9

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 1. Putative microRNA binding sites on Mcl-1 messenger RNA

Panel a: Schematic of the Mcl-1 3’UTR (#NM_021960) nucleotides 1184í4020. Five
microRNAs were predicted to bind and the position of binding to the Mcl-1 transcript is shown
in parentheses. Panel b: Northern blot of the five putative Mcl-1 binding microRNAs. RNA
enriched for small RNA (<200nt's) from H69 cells was separated and probed for the indicated
microRNAs. Note the robust expression of mir-29. Size markers are from SybrGreen-stained
gels prior to transfer; 5.8S and 5S are endogenous rRNAs, 26 nt and 18 nt refer to synthetic
oligodeoxynucleotides run in an adjacent lane.
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Figure 2. Reciprocal expression of mir-29b and Mcl-1
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Panel a: Total cellular protein from immortalized non-malignant H69 cells and malignant
KMCH cells was probed using a Mcl-1 antibody. Actin was used as a loading control. Panel
b: Northern blot for mir-29b using RNA enriched for small RNAs from H69 and KMCH cells.
Note that both precursor and mature mir-29b are decreased in KMCH cells. As a loading
control, an RNA probe against the small housekeeping RNA U6 (106 nt) was used. Panel c:
Quantitative RT-PCR for mir-29b using total RNA from H69 and KMCH cells. Results
expressed as copies of mir-29b per copy of Z30 RNA (mean +/í SEM; p < 0.05).
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Figure 3. Mcl-1 protein level is negatively regulated by mir-29b

Panel a: Fluorescently-labeled pre-mir-29b was generated by in vitro transcription
(Supplemental Methods) and transfected into KMCH cells. After 24 hours, cells were counterstained with the nuclear stain DAPI, and photographed. For comparison, untransfected cells
are shown. Panel b: Northern blot using small RNA from KMCH cells transfected with 20 or
50 nM precursor mir-29b (not fluorescently-tagged) compared to mock-transfected cells. The
mature, processed form (23 nt) is shown, demonstrating that the transfected RNA is processed.
U6 was probed as a loading control. Panel c: Mcl-1 immunoreactivity in KMCH cells
transfected with precursor mir-29b. A Texas red-conjugated secondary antibody was used, and
cells were photographed under confocal microscopy. Panel d: Western blots of total cellular
protein from KMCH cells transfected with a mir-29b expression vector (p29b). Control cells
were transfected with 1 ȝg of pCDNA, experimentals were transfected with 0.5 or 1 ȝg p29b.
Actin was used as a loading control. Panel e: Northern blot on total RNA isolated from KMCH
cells stably transfected with p29b. Two lines were generated, K-mir-29í6 and K-mir-29í19.
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The housekeeping RNA U6 was probed as a loading control. Panel f: Western blot of total
protein from KMCH, K-mir-29í6, and K-mir-29í19 (stably overexpress mir-29b). Actin was
used as a loading control.
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Figure 4. Effect of the putative mir-29 binding site derived from the Mcl-1 3’UTR on luciferase
expression

Panel a: Alignment of mir-29b with the insert derived from the Mcl-1 3’UTR. Note the
complementarity at the 5’ end of mir-29b, where the crucial seed region is located. A singlebase mutant insert was also synthesized, as shown. Inserts were cloned into the 3’ UTR of the
p-Mir-Report vector. Panel b: Luciferase activity in HeLa cells transiently transfected with the
luciferase construct alone, or cotransfected with an expression plasmid for mir-29b (p29b).
Luciferase vectors were parental (pLuc), luciferase with the Mcl-1-derived 3’UTR insert
(pLuc-Mcl-1 3’UTR), or luciferase with the mutated insert (pLuc-Mutant 3’UTR). Mean ±
SEM, *p<0.01.
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Figure 5. Sensitivity to apoptosis is increased after transfection of mir-29b

Panel a: KMCH cells were transfected with pre-mir-29b RNA or control RNA of the same
length (antisense) at 50 nM. After 22 hours, TRAIL was added where indicated at 2 ng/mL in
fresh media and the cells were incubated for 4 hours. Cells were then stained with DAPI and
cells with apoptotic morphology were counted. Mean ± SEM, **p<0.001. Panel b: In parallel,
cells were transfected and treated with TRAIL as in panel a, but after 4 hours caspase 3/7-like
(DEVDase) activity was measured. Mean ± SEM, *p<0.01.

Oncogene. Author manuscript; available in PMC 2008 June 20.

Mott et al.

Page 15

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 6. Antagonism of mir-29b protects cells from apoptosis
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Panel a: Western blot of total protein isolated from non-malignant H69 cells and malignant
KMCH cells transfected with control RNA, pre-mir-29b, or the mir-29 antagonist
oligonucleotide, LNA (50nM each). Panel b. Apoptotic morphology measured as in Figure 5
on H69 and KMCH cells transfected as above. Note that H69 cells are sensitive to TRAIL
killing, as noted in previous studies, while KMCH cells are relatively resistant unless mir-29b
is transfected. Mean ± SEM, **p<0.0001 compared to vehicle treated control; # p<0.01
compared to TRAIL-treated mir-29; ## p<0.0001 compared to TRAIL-treated mir-29. Panel
c: Caspase 3/7-like activity (DEVDase) on cells transfected as above. Caspase activity parallels
the apoptosis counts using morphology. Mean ± SEM, *p<0.01 compared to vehicle treated
control; **p<0.0001 compared to vehicle treated control; ## p<0.0001 compared to TRAILtreated mir-29.
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